Skip to main content
Shanghai Junshi Biosciences Co.,Ltd. logo

Shanghai Junshi Biosciences Co.,Ltd. — Investor Relations & Filings

Ticker · 688180 ISIN · CNE1000041Z1 LEI · 300300L36FLCKN0WXW06 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,056 across all filing types
Latest filing 2026-03-13 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688180

About Shanghai Junshi Biosciences Co.,Ltd.

https://www.junshipharma.com/

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies. The company maintains a diverse pipeline targeting oncology, immunology, metabolic disorders, neurological diseases, and infectious diseases. A pioneer in its field, it developed Toripalimab, the first domestically produced anti-PD-1 monoclonal antibody to receive marketing approval in its home market. Its integrated R&D platform encompasses the entire drug development lifecycle, from initial discovery and clinical evaluation to large-scale manufacturing and global commercialization. The company collaborates with international partners to expand the reach of its innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, aiming to provide effective and affordable treatment options for patients globally.

Recent filings

Filing Released Lang Actions
君实生物2025年度独立非执行董事述职报告（郦仲贤）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Non-Executive Director's Annual Report" for the year 2025, authored by an independent non-executive director of the company. It details the director's activities, attendance at meetings, communication with auditors, review of financial reports, oversight of related party transactions, and other governance-related duties during the year. The content focuses on the director's role and responsibilities rather than presenting full financial statements or audit results. It is a detailed report on board/management activities and oversight rather than a full annual report, audit report, or earnings release. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is under 5,000 characters, but it is a substantive report, not merely an announcement or certification, so it is not RPA or RNS. Hence, the classification is MANG with high confidence.
2026-03-13 Chinese
君实生物关于新增认定核心技术人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shanghai Junshi Biosciences Co., Ltd. about the addition of a new core technical personnel, Ms. Zou Jianjun, including her detailed resume and the change in core technical personnel. It is a corporate announcement regarding management or key personnel changes, not a financial report, earnings release, or regulatory filing. There is no indication of financial data, voting results, or legal proceedings. The content fits best under Board/Management Information (MANG) as it relates to changes in senior management or key personnel.
2026-03-13 Chinese
君实生物2025年度环境、社会和公司治理（ESG）报告
Environmental & Social Information Classification · 98% confidence The document is a comprehensive Environmental, Social, and Governance (ESG) report published annually, detailing the company’s ESG management framework, governance practices, environmental compliance, social initiatives, stakeholder communication, and other sustainability metrics. It follows sustainability reporting guidelines (HKEX ESG Guide, SSE’s sustainable development reporting, GRI Standards) and covers the period January 1, 2025 to December 31, 2025. This aligns precisely with the Environmental & Social Information category (Code: SR).
2026-03-13 Chinese
君实生物关于董事会战略委员会调整为董事会战略与ESG委员会、修订及制定部分内部管理制度的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of Shanghai Junshi Biosciences regarding the adjustment of the Board's Strategic Committee to include ESG responsibilities and the formulation of a remuneration management system for directors and senior management. It references changes in internal management systems and governance practices, citing relevant laws and listing rules. The document does not contain financial statements or detailed financial data but focuses on governance structure and management policies. The document length is short (1162 characters) and it is an announcement of changes in board committee structure and management policies, fitting the category of Board/Management Information (MANG).
2026-03-13 Chinese
容诚会计师事务所（特殊普通合伙）关于上海君实生物医药科技股份有限公司2025年度营业收入扣除情况的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) concerning the company's 2025 fiscal year revenue deduction situation. It is issued by an accounting firm and references compliance with specific Shanghai Stock Exchange Sci-Tech Innovation Board listing rules and self-regulatory guidelines related to financial delisting indicators. The document includes an audit opinion on a specific financial schedule (revenue deduction table) prepared by management, and it explicitly states it is a special audit report rather than a full annual report or interim report. The document length is 2852 characters, which is relatively short but contains substantive audit content and opinion. This matches the definition of an Audit Report / Information (AR) as it is a standalone audit report focusing on a specific financial aspect, not a full annual report or earnings release. Therefore, the correct classification is AR with high confidence. FY 2025
2026-03-13 Chinese
君实生物2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2025 by Shanghai Junshi Biosciences Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content focuses on internal control assessment rather than full financial statements or annual performance. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial data and analysis. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive evaluation content rather than just an announcement or certification. The document fits best under Audit Report / Information (AR) as it is a standalone internal control evaluation report detailing applied standards, findings, and conclusions about internal controls, which aligns with the AR category definition. FY 2025
2026-03-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.